ClinicalTrials.gg
CompletedNCT05858047Updated Apr 30, 2024

An Investigational Study to Evaluate Experimental Medication SYHX1901 Tablets With Moderate to Severe Plaque Psoriasis

A Phase 2 interventional study of Placebo and SYHX1901 in Effects, Drug Side, sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
93
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China — 14 open to participants now, 15 under way, none of them phase 3. Drug-Related Side Effects and Adverse Reactions · China.

Enrollment
9th of 33
93 · median 44
Started
2023
with 5 others
Phase 2
10 of 53
1 open now
Registered
40th of 53
by date

Among the 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China, this one is the 9th largest by enrollment of the 33 interventional ones that give a count, is one of 6 that started in 2023, is one of 10 in phase 2, and was the 40th registered.

Drug-Related Side Effects and Adverse Reactions

449 studies on the registry are indexed under Drug-Related Side Effects and Adverse Reactions; 77 are open to participants now.

Browse Drug-Related Side Effects and Adverse Reactions studies →

Open to participants now

14 of the 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 55 Drug-Related Side Effects and Adverse Reactions studies recruiting now, 37 (67%) set no upper age limit and 15 (27%) stop at 75 or younger; 14 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Drug-Related Side Effects and Adverse Reactions with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of different doses of SYHX1901 tablets in the treatment of moderate to severe plaque psoriasis in order to select doses for further clinical trials.

Read the detailed description

This is a multicenter, randomized, double-blind, placebo-controlled phase Ⅱ study to evaluate the efficacy and safety of three different doses of SYHX1901 tablets compared with placebo in the treatment of moderate to severe plaque psoriasis. The total duration of the study will be 20 weeks which will be comprised of: a screening period (4 weeks); an efficacy assessment period (12 weeks) and a follow-up assessment period (4 weeks). Eligible subjects will be randomly assigned to SYHX1901 60 mg qd, 90 mg qd, 180 mg qd or placebo group at a 1:1:1:1 ratio for continuous oral administration for 12 weeks. The presence or absence of treatment with biological agents will be a stratification factor. Subjects will be monitored for the safety throughout the study.

03

Conditions studied

  • Effects, Drug Side
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects fully understand and voluntarily participate in this study and sign ;
  2. Age ≥18 and ≤ 75 years old;
  3. Subjects with a clinical diagnosis of stable moderate-to-severe plaque psoriasis with a history ≥6 months before randomization; Subjects with stable moderate-to-severe plaque psoriasis defined as meeting all four of the following criteria simultaneously:

    1. Subject must be diagnosed of chronic plaque psoriasis with no morphological changes or significant outbreaks of disease activity assessed by the investigator;
    2. Subject must be a candidate for systemic treatment or phototherapy assessed by the investigator;
    3. Body Surface Area (BSA) affected by plaque-type psoriasis ≥10% at screening and baseline;
    4. PASI score of ≥12 and Physician's Global Assessment (PGA) score ≥3 at screening and baseline;
  4. Negative blood pregnancy results should be provided 14 days (inclusive) and 3 days (inclusive) prior to initial dosing, and subjects and their partners should voluntarily take measures considered effective by the investigator during the study period and for at least 28 days after the study;
  5. Subjects must be volunteer and be able to complete study procedures and follow-up examinations.

Exclusion criteria

Exclusion Criteria:

  1. Forms of psoriasis other than plaque psoriasis (Guttate psoriasis、erythrodermic psoriasis、Pustular psoriasis、Drug-induced psoriasis);
  2. Previous or current disease;
  3. Other active skin conditions that may affect the clinical evaluation of psoriasis;
  4. Active infection or fever at randomization;
  5. Severe bacterial, fungal, or viral infection requiring hospitalization/intravenous drug treatment within 60 days prior to randomization;
  6. Any proven history of untreated bacterial infection within 60 days prior to randomization;
  7. Any existing evidence of chronic infection;
  8. Any proven history of infection of a joint prosthesis or receiving antibiotics for a suspected joint prosthesis infection;
  9. Received within 60 days before randomization or scheduled to receive live vaccine within 60 days after the end of the study;
  10. History of severe herpes zoster or sever herpes simplex infection;
  11. Abnormal virus (HBV) related check during screening;
  12. virus (HCV) antibody positive at screening;
  13. antibody or treponema pallidum antibody positive;
  14. Any known or suspected condition of congenital or acquired immunodeficiency;
  15. Tuberculosis (TB);
  16. Symptoms or signs of progressive or uncontrolled kidney, liver, blood, gastrointestinal, endocrine, lung, heart, neurological, psychiatric, or brain disease, or with other chronic diseases that the investigator has determined are not suitable for participation in this clinical trial;
  17. History of or lymphoproliferative disease within 5 years (except for cured basal cell carcinoma and in situ cervical cancer);
  18. Major surgery within 8 weeks before randomization or surgery planned during the study;
  19. Uncontrolled hypertension, systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg after systemic treatment;
  20. Having unstable cardiovascular disease defined as presence of a clinical cardiovascular event in the last 3 months or hospitalized for heart disease within the last 3 months; or ≥3 grade, or abnormal suggesting and assessed by the investigator as carrying unforeseen risks;
  21. History of arterial or venous thrombosis or at high risk;
  22. Significant gastrointestinal disorders, such as erosion, hemorrhagic gastroenteritis, a history of bleeding from gastrointestinal ulcers, inflammatory bowel disease, and other disorders that investigator consider to be at risk for gastrointestinal perforation or that may interfere with drug ingestion, transport, or absorption;
  23. Uncontrolled hyperlipidemia (TG>2.3 mmol/L and/or LDL>3.4 mmol/L) after standard treatment;
  24. Low body weight (weight ≤45 kg or ≤18 kg/m\^2);
  25. BMI ≥30kg/m\^2, (severe obesity);
  26. Have received local anti-psoriasis therapy within 2 weeks prior to randomization; If topical moisturizers have been used within 2 weeks, they should be continued throughout the trial, with the same frequency and dose until the end of the study;
  27. Have used physical therapy within 4 weeks prior to randomization (including photochemotherapy, ultraviolet therapy);
  28. Systemic treatments:

    1. Systemic anti-psoriasis therapy within 4 weeks before study drug initiation;
    2. Leflunomide within 6 months before study drug initiation;
    3. Opioid analgesics within 4 weeks before study drug initiation;
    4. Lithium and antimalarial drugs within 4 weeks before study drug initiation;
    5. Any potent inhibitor/inducer within 4 weeks before study drug initiation;
    6. Any P-gp potent inhibitor/inducer within 4 weeks before study drug initiation;
    7. Thymosin administered by injection or orally within 4 weeks before study drug initiation;
    8. Use of BCRP-sensitive substrate drugs assessed by the investigator during the study;
  29. Biological agents:

    1. Exposure to any biological drug directly targeting IL-17 or IL-12, or IL-23 within 6 months prior to randomization ;
    2. Exposure to any TNF monoclonal antibody within 2 months prior to randomization;
    3. Exposure to any monoclonal antibodies against CD20 within 6 months prior to randomization;
    4. Exposure to any T cell or B cell modulators or integrin pathway modulators within 3 months prior to randomization;
    5. Any other biological drugs within 5 half-lives before study drug initiation;
  30. Enrolled in a clinical study of any other drug within 3 months or use of any other drugs within 5 half-lives of the investigational treatment before randomization;
  31. History of lack of response to treatment after at least 3 months of treatment with any monoclonal antibody targeting IL-17 or IL-23 at approved doses;
  32. Organ transplantation (except corneal transplantation more than 3 months before the initiation of the investigational drug);
  33. Impossible to avoid prolonged daylight exposure during the trial, or to plan to use UV health rooms or other UV light sources;
  34. Laboratory abnormalities of clinical significance assessed by the investigator to pose a risk:

    1. or ALT ≥ 2×;
    2. Total and/or direct bilirubin >2×ULN;
    3. Neutrophil absolute value (NEUT#) \<1.5×10\^9/L;
    4. Electrolyte imbalance;
  35. History of alcohol and drug abuse or test positive for drug abuse;
  36. History of neurological or psychiatric disorders, such as depression, suicidal tendencies, epilepsy, dementia, etc;
  37. Any other medical and/or social reasons identified by the investigator as inappropriate for participation in the study;
  38. Members of the research team and their immediate families.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
93 participants (actual)

Study arms

  • Placebo comparator
    Group I (Placebo)

    Placebo will be administered orally (PO) for 12 weeks.

    Drug: Placebo

  • Experimental
    Group Ⅱ (SYHX1901 60 mg)

    SYHX1901 will be administered orally (PO) for 12 weeks.

    Drug: SYHX1901

  • Experimental
    Group III (SYHX1901 90 mg)

    SYHX1901 will be administered orally (PO) for 12 weeks.

    Drug: SYHX1901

  • Experimental
    Group Ⅳ (SYHX1901 180 mg)

    SYHX1901 will be administered orally (PO) for 12 weeks.

    Drug: SYHX1901

Interventions

  • DrugPlacebo

    Administered orally, once daily (QD)

  • Administered orally, once daily (QD)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a Psoriasis Area and Severity Index Score ≥75% (PASI 75) response

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving a Psoriasis Area and Severity Index Score ≥50% (PASI 50) response

    Time frame: Week 12

  2. Percentage of Participants Achieving a Physician Global Assessment (PGA) of 0 or 1

    Time frame: Week 12

  3. Change from Baseline in Body Surface Area (BSA) affected with Psoriasis to Week 12

    Time frame: Week 12

  4. Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) of 0 or 1

    Time frame: Week 12

Other outcomes

  1. Incidence of AEs and SAEs

    Time frame: Time Frame:Week 16

07

Study locations

1 site
  • Huashan Hospital Affiliated to Fudan University
    Shanghai, Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Feb 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2023
First posted
May 15, 2023
StartActual
Apr 11, 2023
Primary completionActual
Feb 21, 2024
CompletionActual
Feb 21, 2024
Last update
Apr 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05858047
Responsible party
Sponsor
First posted
May 15, 2023
Start date
Apr 11, 2023
Primary completion
Feb 21, 2024
Completion
Feb 21, 2024
Last update
Apr 30, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYHX1901

Start the discussion